Growth responses during the first year of growth hormone therapy: evaluation of height velocity targets

The status of growth hormone (GH) secretion together with the effect of GH therapy was studied in six children with achondroplasia. One patient had impaired GH secretion, which may, in part, be due to obesity. The pre-GH-treatment height velocity was 3.8±0.7 cm/year, but this increased to 6.0±1.0 cm/year in the first year of treatment and to 4.4±0.6 cm/year in the second year. One patient who underwent GH therapy for 4 years showed good response in height velocity. A considerable variation was observed in response to GH therapy within the treated cases.

Download Full-text

Growth hormone therapy in pre-pubertal children with Noonan syndrome: first year growth response and comparison with Turner syndrome

Acta Paediatrica ◽

10.1111/j.1651-2227.1997.tb15175.x ◽

1997 ◽

Vol 86 (9) ◽

pp. 943-946 ◽

Cited By ~ 12

Author(s):

J De Schepper ◽

BJ Otten ◽

I François ◽

J-P Bourguignon ◽

M Craen ◽

...

Keyword(s):

Growth Hormone ◽

Hormone Therapy ◽

Turner Syndrome ◽

Noonan Syndrome ◽

Growth Response ◽

Growth Hormone Therapy ◽

First Year

Download Full-text

Patterns of recombinant growth hormone therapy use and growth responses among children with chronic kidney disease

Pediatric Nephrology ◽

10.1007/s00467-021-05122-8 ◽

2021 ◽

Author(s):

Derek K. Ng ◽

Megan K. Carroll ◽

Frederick J. Kaskel ◽

Susan L. Furth ◽

Bradley A. Warady ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Growth Hormone ◽

Kidney Disease ◽

Hormone Therapy ◽

Growth Hormone Therapy ◽

Growth Responses ◽

Recombinant Growth Hormone

Download Full-text

P-73 DEFINING RESPONSIVENESS TO GROWTH HORMONE THERAPY: FIRST YEAR GROWTH RESPONSE DATA FROM GENENTECHS NATIONAL COOPERATIVE GROWTH STUDY (NCGS)

Growth Hormone & IGF Research ◽

10.1016/s1096-6374(07)70298-8 ◽

2006 ◽

Vol 16 ◽

pp. S37-S38

Author(s):

Ron G Rosenfeld ◽

Henry Anhalt ◽

James Frane ◽

Barbara Lippe ◽

Bert Bakker

Keyword(s):

Growth Hormone ◽

Hormone Therapy ◽

Growth Response ◽

Growth Hormone Therapy ◽

First Year ◽

Growth Study ◽

Response Data ◽

National Cooperative

Download Full-text

Age at Growth Hormone Therapy Start and First-Year Responsiveness to Growth Hormone Are Major Determinants of Height Outcome in Idiopathic Short Stature

Hormone Research in Paediatrics ◽

10.1159/000098707 ◽

2007 ◽

Vol 68 (2) ◽

pp. 53-62 ◽

Cited By ~ 37

Author(s):

Michael B. Ranke ◽

Anders Lindberg ◽

David A. Price ◽

Feyza Darendeliler ◽

Kerstin Albertsson-Wikland ◽

...

Keyword(s):

Growth Hormone ◽

Hormone Therapy ◽

Short Stature ◽

Growth Hormone Therapy ◽

Idiopathic Short Stature ◽

First Year

Download Full-text

Monitoring Adherence Rate to Growth Hormone Therapy and Growth Outcomes in Taiwanese Children Using Easypod Connect: Observational Study

JMIR Pediatrics and Parenting ◽

10.2196/14774 ◽

2021 ◽

Vol 4 (1) ◽

pp. e14774

Author(s):

Pen-Hua Su ◽

Chen Yang ◽

Mei-Chyn Chao ◽

Chung-Lin Chiang

Keyword(s):

Growth Hormone ◽

Observational Study ◽

Hormone Therapy ◽

Growth Hormone Therapy ◽

Recombinant Human Growth Hormone ◽

Height Velocity ◽

Complete Analysis ◽

Adherence Rate ◽

Growth Outcomes ◽

The Mean

Background Adherence to growth hormone therapy is difficult to detect reliably. Devices such as easypod have been developed for electronic recording of injections. The easypod connect observational study (ECOS) was an open-label, observational, multinational, phase IV study conducted in 24 countries around the world. The final results from ECOS in the Taiwanese cohort are reported in this paper. Objective This study aimed to evaluate the adherence and long-term outcomes of growth hormone therapy in pediatric subjects using the easypod electromechanical device. Methods Subjects (aged 2-18 years or >18 years without fusion of growth plates) who received Saizen (recombinant human growth hormone, somatropin) via the easypod device were enrolled in this study. The primary objective was to assess the level of adherence in subjects receiving Saizen via easypod. Results In Taiwan, a total of 35 and 13 children fulfilled the criteria of full analysis set and complete analysis set, respectively. The mean (SD) age of the complete analysis set was 12.08 (2.72) years. All subjects were growth hormone–naïve, with 38% (5/13) females. The mean adherence rates of 13 subjects were 87.6% at 3 months and 84.3% at 6 months, that of 8 subjects was 81.0% at 9 months, and that of 4 subjects was 91.6% at 1 year. After 1 year of treatment, subjects had a median (Q1:Q3) change in height SD score of 0.30 (0.06:0.48), median height velocity of 6.50 (4.33:8.24) cm/year, and median change in height velocity SD score of 1.81 (–0.04:3.52). Conclusions With the easypod device, patients with inadequate adherence and poor response to treatment can be identified. Adherence to growth hormone therapy administered via easypod was generally high in the first year of treatment but the adherence gradually decreased over time. Overall, growth outcomes after 1 year indicated a positive growth response to growth hormone treatment. Future efforts should be focused on personalized management of adherence by using the easypod system.

Download Full-text

Monitoring Adherence Rate to Growth Hormone Therapy and Growth Outcomes in Taiwanese Children Using Easypod Connect: Observational Study (Preprint)

10.2196/preprints.14774 ◽

2019 ◽

Author(s):

Pen-Hua Su ◽

Chen Yang ◽

Mei-Chyn Chao ◽

Chung-Lin Chiang

Keyword(s):

Growth Hormone ◽

Observational Study ◽

Hormone Therapy ◽

Growth Hormone Therapy ◽

Recombinant Human Growth Hormone ◽

Height Velocity ◽

Complete Analysis ◽

Adherence Rate ◽

Growth Outcomes ◽

The Mean

BACKGROUND Adherence to growth hormone therapy is difficult to detect reliably. Devices such as easypod have been developed for electronic recording of injections. The easypod connect observational study (ECOS) was an open-label, observational, multinational, phase IV study conducted in 24 countries around the world. The final results from ECOS in the Taiwanese cohort are reported in this paper. OBJECTIVE This study aimed to evaluate the adherence and long-term outcomes of growth hormone therapy in pediatric subjects using the easypod electromechanical device. METHODS Subjects (aged 2-18 years or >18 years without fusion of growth plates) who received Saizen (recombinant human growth hormone, somatropin) via the easypod device were enrolled in this study. The primary objective was to assess the level of adherence in subjects receiving Saizen via easypod. RESULTS In Taiwan, a total of 35 and 13 children fulfilled the criteria of full analysis set and complete analysis set, respectively. The mean (SD) age of the complete analysis set was 12.08 (2.72) years. All subjects were growth hormone–naïve, with 38% (5/13) females. The mean adherence rates of 13 subjects were 87.6% at 3 months and 84.3% at 6 months, that of 8 subjects was 81.0% at 9 months, and that of 4 subjects was 91.6% at 1 year. After 1 year of treatment, subjects had a median (Q1:Q3) change in height SD score of 0.30 (0.06:0.48), median height velocity of 6.50 (4.33:8.24) cm/year, and median change in height velocity SD score of 1.81 (–0.04:3.52). CONCLUSIONS With the easypod device, patients with inadequate adherence and poor response to treatment can be identified. Adherence to growth hormone therapy administered via easypod was generally high in the first year of treatment but the adherence gradually decreased over time. Overall, growth outcomes after 1 year indicated a positive growth response to growth hormone treatment. Future efforts should be focused on personalized management of adherence by using the easypod system.

Download Full-text